Myriad Genetics (MYGN) Cost of Revenue (2009 - 2026)

Myriad Genetics has disclosed Cost of Revenue across 18 years of filings, most recently posting $62.8 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 1.78% year-over-year to $62.8 million; the TTM figure through Mar 2026 stood at $258.1 million (down 8.21% YoY), while the FY2025 annual figure was $247.9 million, down 12.74% from the prior year.
• Cost of Revenue steadied at $62.8 million in Q1 2026, from $63.0 million in the prior quarter.
• Over the last five years, Cost of Revenue for MYGN reached as high as $118.7 million in Q4 2022 and fell as low as $48.0 million in Q1 2022.
• The 5-year median for Cost of Revenue is $62.8 million (2026), against an average of $68.5 million.
• Annual changes were most pronounced in 2022 — Cost of Revenue soared 192.73% — and 2025, when it plunged 31.22%.
• A 5-year view of Cost of Revenue shows it stood at $118.7 million in 2022, then slipped by 3.45% to $114.6 million in 2023, then slipped by 20.07% to $91.6 million in 2024, then sank by 31.22% to $63.0 million in 2025, then retreated by 0.32% to $62.8 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $62.8 million, $63.0 million, and $71.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.